<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">0370500</journal-id><journal-id journal-id-type="pubmed-jr-id">441</journal-id><journal-id journal-id-type="nlm-ta">Am J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Am J Ophthalmol</journal-id><journal-title-group><journal-title>American journal of ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0002-9394</issn><issn pub-type="epub">1879-1891</issn></journal-meta><article-meta><article-id pub-id-type="pmid">40015588</article-id><article-id pub-id-type="pmc">12697009</article-id><article-id pub-id-type="doi">10.1016/j.ajo.2025.02.030</article-id><article-id pub-id-type="manuscript">HHSPA2126947</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Patient Navigators Improve In-Office Eye Exam Adherence After Community Eye Screenings in a Randomized Clinical Trial: NYC-SIGHT Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>HARK</surname><given-names>LISA A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>GORROOCHURN</surname><given-names>PRAKASH</given-names></name></contrib><contrib contrib-type="author"><name><surname>PIZZI</surname><given-names>LAURA T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>JUTKOWITZ</surname><given-names>ERIC</given-names></name></contrib><contrib contrib-type="author"><name><surname>GOULAK</surname><given-names>ANNETTE M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>MARURI</surname><given-names>STEFANIA C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>HARIZMAN</surname><given-names>NOGA</given-names></name></contrib><contrib contrib-type="author"><name><surname>HOROWITZ</surname><given-names>JASON D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>PARK</surname><given-names>LISA</given-names></name></contrib><contrib contrib-type="author"><name><surname>WANG</surname><given-names>QING</given-names></name></contrib><contrib contrib-type="author"><name><surname>DIAMOND</surname><given-names>DANIEL F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>VALENZUELA</surname><given-names>IVES A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>TORRES</surname><given-names>DESIREE R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>WANG</surname><given-names>YUJIA</given-names></name></contrib><contrib contrib-type="author"><name><surname>SHARMA</surname><given-names>TARUN</given-names></name></contrib><contrib contrib-type="author"><name><surname>LIEBMANN</surname><given-names>JEFFREY M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>CIOFFI</surname><given-names>GEORGE A.</given-names></name></contrib><aff id="A1">Department of Ophthalmology (L.H., A.G., N.H., J.H., L.P., Q.W., D.D., I.V., T.S., J.L., G.C.), Columbia University, Vagelos College of Physicians and Surgeons, New York, New York, USA.; Edward S. Harkness Eye Institute (L.H., S.M., N.H., J.H., Q.W., D.D., I.V., D.T., Y.W., T.S., J.L., G.C.), Columbia University Irving Medical Center, New York, New York, USA.; Department of Biostatistics (P.G.), Columbia University Mailman School of Public Health, New York, New York, USA.; Center for Health Outcomes, Policy, and Economics (L.P.), Rutgers University Ernest Mario School of Pharmacy, Piscataway, New Jersey, USA.; Department of Health Services, Policy &#x00026; Practice (E.J.), Brown University School of Public Health, Providence, Rhode Island, USA.</aff></contrib-group><author-notes><corresp id="CR1">Inquiries to Lisa A. Hark, Columbia University Vagelos College of Physicians and Surgeons, New York, New York 10032, USA; <email>lahl12@cumc.columbia.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>4</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>12</month><year>2025</year></pub-date><volume>274</volume><fpage>54</fpage><lpage>66</lpage><abstract id="ABS1"><sec id="S1"><label>&#x02022;</label><title>PURPOSE:</title><p id="P1">To assess the effectiveness and cost of patient navigators in improving adherence to an initial in-office eye exam following community-based eye health screenings and referral to ophthalmology among underserved populations.</p></sec><sec id="S2"><label>&#x02022;</label><title>DESIGN:</title><p id="P2">5-year prospective, cluster-randomized <bold>clini</bold>cal trial.</p></sec><sec id="S3"><label>&#x02022;</label><title>PARTICIPANTS:</title><p id="P3">Eligible individuals aged 40 years and older were recruited from affordable housing developments and senior centers in Upper Manhattan.</p></sec><sec id="S4"><label>&#x02022;</label><title>METHODS:</title><p id="P4">Demographics, social determinants of health, clinical characteristics, and access to eye care were collected. Eye health screenings included visual acuity, intraocular pressure, and fundus photography. Those diagnosed with glaucoma, suspected glaucoma, retinal abnormalities, cataracts, or other ocular conditions were referred for in-office eye exams, with initial appointments scheduled by study staff. Navigator Intervention participants received appointment scheduling support for 10 months, Usual Care participants did not receive navigator assistance. T tests, chi-square tests and multivariate stepwise logistic regression analyzed factors associated with adherence. Cost-effectiveness analysis was conducted alongside the study.</p></sec><sec id="S5"><label>&#x02022;</label><title>MAIN OUTCOME MEASURES:</title><p id="P5">Adherence to the initial in-office eye exam for those referred to ophthalmology.</p></sec><sec id="S6"><label>&#x02022;</label><title>RESULTS:</title><p id="P6">Of 468 referred participants, 47% (n = 220/468) attended the initial in-office eye exam. Adherence rates: Navigator Intervention (51.8%) versus Usual Care (38.1%). Of those who attended the in-office eye exam, mean age: 70.2 &#x000b1; 11.3 years; 65.5% female; 46.8% African American, 47.3% Hispanic. Participants in the Navigator Intervention group had higher odds of adhering to the initial in-office eye exam compared to those receiving Usual Care (OR = 1.529; 95% Cl (1.023, 2.285)). Participants who spoke English as their primary language also had higher odds of adhering to the initial eye exam (OR = 1.815; 95% CI (1.211, 2721)). Cost per participant in the Navigator Intervention group who attended the in-office eye exam: $24.25 vs. $33.03 per Usual Care participant.</p></sec><sec id="S7"><label>&#x02022;</label><title>CONCLUSIONS:</title><p id="P7">Patient navigators improved adherence to in-office eye exams following community-based eye health screenings and referral to ophthalmology among an underserved population. The Navigator Intervention resulted in cost savings with an incremental cost-effectiveness difference of $8.78 less per participant randomized to the Navigator Intervention group. (Am J Ophthalmol 2025;274: 54&#x02013;66.</p></sec></abstract></article-meta></front><body><sec id="S8"><title>INTRODUCTION</title><p id="P8">According to the United States (US) Centers for Disease Control and Prevention (CDC), glaucoma, diabetic retinopathy, cataracts, and age-related macular degeneration are the leading causes of vision impairment and blindness in the US, representing significant public health problems and increasing medical expenses.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Underserved populations bear a disproportionate burden of these eye diseases, which significantly affect quality-of-life.<sup><xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R5" ref-type="bibr">5</xref></sup> Abundant evidence indicates that vision and eye health disparities exist due to multilevel social determinants of health (SDOH) which act as barriers to eye care, with multiple studies finding clear associations between SDOH and vision impairment.<sup><xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref></sup> The National Eye Institute (NEI)&#x02019;s Strategic Plan: <italic toggle="yes">Vision for the Future 2021&#x02013;2025</italic> highlights the need to address multi-level SDOH to improve detection and reduce eye disease burden in underserved communities.<sup><xref rid="R8" ref-type="bibr">8</xref></sup></p><p id="P9">Patient navigators have emerged as a promising intervention following community-based eye health screenings to support follow-up eye care, however, more research is needed to test implementation strategies in ophthalmology.<sup><xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref></sup> Dohan and Schrag identified 2 types of definitions for patient navigation, both of which directly address SDOH: &#x0201c;service-focused&#x0201d; and &#x0201c;barrier-focused,&#x0201d; and we believe both are applicable to the field of ophthalmology.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Based on the service-focused definitions, patient navigators can connect individuals to resources (eye health screenings) and assist participants in scheduling appointments if they are referred for in-office eye exams (access to care). Barrier-focused definitions explain that patient navigators identify and help remove impediments (such as transportation) that prevent participants from attending in-office eye exams, adhering to follow-up appointments, taking medications, and/or undergoing laser treatment or ocular surgery.<sup><xref rid="R13" ref-type="bibr">13</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref></sup></p><p id="P10">In 2019, Columbia University Department of Ophthalmology (Principal Investigator L. Hark) received 5 years of funding through a CDC Cooperative Agreement: <italic toggle="yes">Improving Detection and Management of Glaucoma and Other Eye Diseases Among High-Risk Populations</italic>.<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup> This community-based eye health screening study, (NYC-SIGHT), aimed to better engage populations most at risk and least likely to have access to eye care in order to detect and manage glaucoma and other ocular diseases.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> The study reached underserved populations with the greatest need for eye care by targeting neighborhoods of Harlem (65% African American race) and Washington Heights (70% Hispanic/Latino ethnicity) and tested a Navigator Intervention to support in-office eye exam adherence for those referred to ophthalmology for in-office eye care and ocular testing/imaging.<sup><xref rid="R16" ref-type="bibr">16</xref></sup></p><p id="P11">This paper describes demographics, SDOH, and clinical factors associated with adherence to an initial in-office eye exam among individuals referred to ophthalmology following community-based eye health screenings. The paper also presents the cost analysis and cost per case detected for those who attended the in-office eye exam.</p></sec><sec id="S9"><title>METHODS</title><sec id="S10"><label>&#x02022;</label><title>STUDY DESIGN:</title><p id="P12">The NYC-SIGHT is a 5-year prospective, cluster-randomized clinical trial. Details regarding the methods, baseline results, and referral to ophthalmology rates have been previously described in detail.<sup><xref rid="R16" ref-type="bibr">16</xref>&#x02013;<xref rid="R18" ref-type="bibr">18</xref></sup> The New York City Housing Authority (NYCHA) development (location) was chosen as the unit of randomization, and 10 developments in Harlem and Washington Heights provided access to 6640 underserved residents who live in close proximity to the Columbia University Harkness Eye Institute and Harlem Hospital Ophthalmology. These developments have a high proportion of men and women of diverse race/ethnicity with high rates of inadequate eye care. A 2:1 cluster randomization scheme was established by the study biostatistician, with 7 developments assigned to the Navigator Intervention and 3 developments assigned to Usual Care. A cluster-randomized design was chosen to prevent contamination. It would be impossible to provide vision screening, eye exams and eyeglasses to only some residents living in the same housing development, as crossovers would be common and dissatisfaction in the comparison arm would be likely.</p><p id="P13">This 2:1 cluster randomization study design (by housing development) aimed to increase the number of participants receiving the Navigator Intervention, based on the hypothesis that over 1- year, study participants referred to ophthalmology following a community-based eye health screenings and randomized to the Navigator Intervention group will have 60% adherence to the initial in-office eye exam compared to 40% in Usual Care.</p><p id="P14">Columbia University Irving Medical Center Institutional Review Board (IRB)/Ethics Committee (#AAAR9162) approved the study and all aspects adhered to the tenets of the Declaration of Helsinki and are in compliance with the Health Insurance Portability and Accountability Act (HIPAA). Informed consent was obtained from all participants prior to enrollment and the study was registered on <ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04271709" ext-link-type="uri">NCT04271709</ext-link>) on 2/20/2020.</p></sec><sec id="S11"><label>&#x02022;</label><title>TARGET POPULATION:</title><p id="P15">Recruitment occurred in Harlem and Washington Heights, targeting individuals living at or below the <ext-link xlink:href="http://NYC.gov" ext-link-type="uri">NYC.gov</ext-link> poverty measure.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Target enrollment was 1500 participants, which was approximately 22% of the sample frame of 6640 (number of adults and seniors living in the 10 NYCHA developments), however, study enrollment was delayed for 1 year during the COVID-pandemic, and when recruitment was resumed in 2021, 10% of NYCHA residents participated.</p></sec><sec id="S12"><label>&#x02022;</label><title>INCLUSION CRITERIA:</title><p id="P16">Eligible participants were individuals aged 40 years and older living in a NYCHA affordable housing developments or members of Department for the Aging (DFTA) senior center aged 60 years and older who consented to an eye health screening.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> Those who met the study&#x02019;s inclusion criteria provided consent over the telephone or in person, in English or Spanish, by the bilingual trained study coordinators, who also conducted the prescreening assessments.</p></sec><sec id="S13"><label>&#x02022;</label><title>PRESCREENING ASSESSMENT:</title><sec id="S14"><title>Demographic and Social Determinants of Health:</title><p id="P17">Participants reported their date of birth, sex, race/ethnicity, education level, health insurance type, employment status, marital status, and preferred transportation methods to medical appointments.</p></sec><sec id="S15"><title>Clinical Characteristics:</title><p id="P18">Medical and ocular conditions, prescription eyeglasses use, and family history of glaucoma and blindness were documented.</p></sec><sec id="S16"><title>Access to Eye Care:</title><p id="P19">Participants were asked if they ever had a dilated eye exam and if so, approximately when was their last dilated eye exam and their transportation method to this appointment. Participants were also asked if they are currently under the care of an eye doctor and would they like to follow-up with him or her if referred to ophthalmology.</p></sec></sec><sec id="S17"><label>&#x02022;</label><title>PROCEDURES:</title><sec id="S18"><title>Eye Health Screenings:</title><p id="P20">Eye health screenings were conducted in community rooms at NYCHA developments or DFTA senior centers. Visual acuity was measured by trained community health workers using the Snellen eye chart at 20 feet with correction.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> Trained ocular technicians measured intraocular pressure (IOP) in both eyes using the Ic100 iCare rebound tonometer (iCare, Helsinki, Finland).<sup><xref rid="R16" ref-type="bibr">16</xref></sup> In a darkened space, 2 nondilated fundus images of the optic disc and macula of each eye were taken by a trained ocular photographer using an autofocus, hand-held fundus camera (Volk, Pictor Prestige, Mentor, Ohio, USA). Within 24 hours, these images were uploaded by the ocular photographer to a HIPAA-compliant cloud-based database (Forum, Zeiss Oberkochen, Germany). The images were read and graded by 1 study ophthalmologist specializing in retina and 1 specializing in glaucoma.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> Final reading results were based on the worse eye and classified as normal or abnormal with no significant findings, abnormal with significant findings, or unreadable.</p></sec><sec id="S19"><title>Screening Failure:</title><p id="P21">Those with visual acuity 20/40 or worse in either eye, IOP 23&#x02013;29 mmHg, or an unreadable image &#x0201c;failed&#x0201d; the eye health screening and were scheduled to see the study optometrist within 3 weeks in the same community-based location. Participants with an IOP &#x02265;30 mmHg were &#x0201c;fast-tracked&#x0201d; and immediately scheduled with ophthalmology for an in-office glaucoma evaluation within 2 weeks. Those with an abnormal fundus image with significant findings were also referred directly to ophthalmology.</p></sec><sec id="S20"><title>Community-Based Optometric Exam:</title><p id="P22">For those who failed the screening and attended the optometric exam, an ocular technician performed an autorefraction (QuickSee Autorefractor, Plenoptika, Cambridge, MA, USA) to assess for refractive error. The optometrist performed a Trial Lens refraction and conducted a nondilated anterior segment exam using a portable slit lamp and a posterior segment exam using a direct ophthalmoscope (Welch Allyn Panoptic 3.5V, Skaneateles Falls, NY) to detect ocular abnormalities. The optic nerve exam for diagnosing glaucoma and glaucoma suspect was based on the <italic toggle="yes">American Academy of Ophthalmology (AAO) Preferred Practice Pattern Guidelines<sup>&#x000ae;</sup></italic>.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> The optometrist also diagnosed cataracts, retinal abnormalities, and other ocular conditions and referred participants to ophthalmology for an in-office dilated eye exam and further ocular testing/imaging as deemed necessary, and the &#x0201c;reasons for referral&#x0201d; results have been previously published.<sup><xref rid="R23" ref-type="bibr">23</xref>&#x02013;<xref rid="R24" ref-type="bibr">24</xref></sup></p></sec><sec id="S21"><title>Referral for In-Office Eye Exams:</title><p id="P23">All participants referred to ophthalmology for an in-office eye exam, either due to an IOP &#x02265;30 mmHg, an abnormal fundus image finding, or ocular conditions confirmed by the optometrist, were scheduled for an initial in-office eye exam by the study staff within 6 months (+4 months). All eye exam dates were documented in the Research Electronic Data Capture (REDCap) and study staff reviewed EPIC electronic medical records (EMR) each time a participant was scheduled in-order to document appointment adherence over 10 months.</p></sec><sec id="S22"><title>Navigator Intervention Group:</title><p id="P24">Participants in the Navigator Intervention group received additional telephone-based support over a 10-month period from trained patient navigators, specifically with scheduling, rescheduling, and eye exam appointment reminders, and if requested, transportation assistance was provided. Navigator Intervention participants who did not attend the initial eye exam were contacted by the patient navigators and rescheduled. Reasons for not attending were captured in the REDCap call log to assess barriers to adherence.</p></sec><sec id="S23"><title>Usual Care Group:</title><p id="P25">Participants in the Usual Care group referred to ophthalmology were only called to share abnormal image findings and schedule the initial in-office eye exam; they did not receive ongoing eye exam scheduling or transportation support after the initial appointment. Usual Care participants were not contacted if they missed the in-office eye exam.</p></sec><sec id="S24"><title>Definition of Adherence:</title><p id="P26">Attendance at the initial in-office eye exam is the primary outcome of the trial.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> Participants were considered adherent if they attended the recommended initial in-office eye exam within 10 months of the community-based screenings since appointments were scheduled within 6 months after screenings, and an additional 4-month window was permitted in case of rescheduling. Participants who chose to receive follow-up eye care from their own ophthalmologist and did not sign a medical release form were excluded from the analysis.</p></sec><sec id="S25"><title>In-Office Ocular Diagnoses, Follow-up and Treatment Recommendations:</title><p id="P27">Participants who attended the initial in-office eye exam were recommended to follow-up at a variety of intervals depending on their ocular condition(s), including within 4 weeks, 1&#x02013;2 months, 3&#x02013;5 months, 6&#x02013;11 months, or 12 months. Ocular diagnoses were confirmed, and treatment recommendations were captured from the EMR and documented in REDCap by study staff for statistical analysis.</p></sec><sec id="S26"><title>Statistical Analysis:</title><p id="P28">Study data were collected and managed using the REDCap database hosted at Columbia University Mailman School of Public Health and are summarized using means and standard deviations for continuous variables and frequencies, and percentages for categorical variables. Data analysis was performed in IBM SPSS Version 28 (IBM Corp. Armonk, NY).<sup><xref rid="R25" ref-type="bibr">25</xref></sup></p><p id="P29">Primary outcome measure was adherence to the initial in-office eye exam. The randomization groups (Navigator Intervention vs. Usual Care) were compared in terms of demographics and SDOH variables (ethnicity, race, age, sex, employment, education level, marital status, insurance type, transportation needs). Predictors of adherence variables included randomization group, demographic characteristics, SDOH, self-reported medical and ocular history, and eye health screening results.</p></sec><sec id="S27"><title>Assessment of the Primary Outcome:</title><p id="P30">A 2-sample t-test was used to compare mean age between those who attended and those who did not attend the initial in-office eye exam. For categorical variables, chi-square tests were conducted to assess differences in adherence rates. Variables that demonstrated statistical significance were then included in a multivariate stepwise logistic regression model to assess their association with adherence, while adjusting for other variables that were also significant. The stepwise logistic regression model was used because a large number of variables were significant in the univariate analyses. At each step, variables were added based on the alpha-to-enter significance level of 0.05 and the alpha-to-remove significance level was set at 0.1 to exclude variables in the final model. For all analyses, P values of &#x0003c; .05 were considered statistically significant and all tests performed were 2-sided. Odds ratios (OR) were estimated with 95% confidence intervals (CI).</p></sec><sec id="S28"><title>Cost Analysis:</title><p id="P31">A cost analysis was conducted alongside the study to identify staff time and resources of delivering the eye health screenings and optometric exams in a real-world community setting. The cost analysis methods have been previously published and are described in detail.<sup><xref rid="R17" ref-type="bibr">17</xref></sup></p></sec><sec id="S29"><title>Cost Measures Inventory and Assumptions:</title><p id="P32">Cost measures included staff time costs for the on-site eye health screenings, equipment, supplies, optometrist eye exams, personal protective equipment, and travel costs to the sites. Staff time costs were calculated using the Activity-Based Costing method, a micro-costing approach which quantifies the monetary value of personnel required to deliver the screening based on the time and resources required.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> During the study, staff logged time spent on implementation tasks in minutes. Since this recorded time did not include time spent managing the program and overhead (indirect costs), we multiplied their recorded time by a factor of 3 to arrive at a more realistic estimate. All time costs were converted to dollars by multiplying time spent performing each task by hourly wage rates, obtained from 2021 US Bureau of Labor Statistics (BLS) data for the specific types of staff involved (ophthalmic medical technician $19.77/hour, optometrist $60.31/hour, and ophthalmologist $129.85/hour).<sup><xref rid="R27" ref-type="bibr">27</xref></sup> The ophthalmologist time was required for image reading only, since they were not otherwise involved in delivering the intervention. All staff time costs were then inflated by 30.4% to account for fringe benefits. Costs for equipment (without depreciation value), travel, and supplies were obtained from financial accounting records. There were no rental costs for any of the spaces, therefore rental costs and depreciation were not included in the cost analysis. Since the goal of the cost analysis was to estimate the costs of delivering the eye health screening in a real-world community setting, we excluded all costs associated with research, including but not limited to, IRB approval and maintenance, research training, research data collection, investigator meetings, obtaining informed consent, research-related travel, and principal investigator time spent on study oversight.</p></sec><sec id="S30"><title>Cost of Navigator Intervention versus Usual Care:</title><p id="P33">We calculated the costs of delivering the Navigator Intervention by tracking the time patient navigators spent coordinating eye exam appointments and arranging transportation for participants referred to ophthalmology using a REDCap call log. Patient navigators and their approximate wage rate plus fringe benefits was costed using the same approach as previously summarized for screening personnel. For those referred to ophthalmology after the screenings, navigators and study staff logged start and end time in minutes using the REDCap call log during all contact with study participants. Time costs were calculated using the Activity-Based Costing method.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> Since this recorded time did not include time spent managing the program and overhead (indirect costs), we multiplied their recorded time by a factor of 1.5 to arrive at a more realistic estimate. All time costs were converted to dollars by multiplying time spent performing each task by hourly wage rate for the patient navigators and study staff ($25.78/hour including fringe benefits), which was obtained from 2021 US Bureau of Labor Statistics (BLS) data.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Costs of patient navigators were compared to the staff time contacting Usual Care participants.</p></sec><sec id="S31"><title>Cost Effectiveness:</title><p id="P34">For those referred to ophthalmology, we calculated the cost per case for any detected eye disease and cost per participant who attended the in-office eye exam and compared costs between Navigator Intervention and Usual Care participants.</p></sec></sec></sec><sec id="S32"><title>RESULTS</title><p id="P35">A total of 708 participants completed eye health screenings in community settings from March 1, 2021 to May 31, 2022 and 468 participants were referred to ophthalmology (66.1%) for in-office eye exams and ocular testing/imaging. As shown in <xref rid="T1" ref-type="table">Table 1</xref>, no differences were noted in age, sex, employment, or health insurance. Significant differences were noted between the characteristics of referred participants in the Navigator Intervention and Usual Care groups. For example, the Navigator group had more participants who self-identified as Hispanic ethnicity (<italic toggle="yes">P</italic> &#x0003c; .001), spoke Spanish (<italic toggle="yes">P</italic> &#x0003c; .001), had higher education levels (<italic toggle="yes">P</italic> = .005) and were more likely to be married or have domestic partner (<italic toggle="yes">P</italic> = .048) (<xref rid="T1" ref-type="table">Table 1</xref>).<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> The majority of participants across both groups had health insurance (97%), at least 73% wore eye glasses, yet 68.5% in the Navigator group and 65.6% in the Usual Care group reported no access to an eye care provider.</p><sec id="S33"><title>Navigator Intervention Findings:</title><p id="P36">Of the 468 participants referred (Navigator Intervention: n = 305, Usual Care: n = 163), 220 participants (47%) adhered to the initial in-office eye exam; of these, 158 participants (51.8%) were randomized to the Navigator Intervention group versus 62 participants (38.1%) from the Usual Care group, demonstrating a significantly greater proportion of participants randomized to the Navigator Intervention group attending the in-office eye exam (<italic toggle="yes">P</italic> = 0.004) (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="F1" ref-type="fig">Figure 1</xref>). Reasons for not attending the in-office eye exam are shown in <xref rid="F1" ref-type="fig">Figure 1</xref>.</p></sec><sec id="S34"><title>Demographics:</title><p id="P37">Baseline demographic and clinical characteristics for those who attended the in-office eye exam, compared to those who did not attend, are shown in <xref rid="T2" ref-type="table">Table 2</xref>. Those who adhered (n = 220) had a mean age of 70.2 years (standard deviation [SD] +/&#x02212;11.3) (age range 40&#x02013;98 years), with the majority (60.9%) aged 60 to 79 years. Additionally, 65.5% were female; 46.8% were of African American race; and 47.3% were of Hispanic ethnicity.</p></sec><sec id="S35"><title>Social Determinants of Health:</title><p id="P38">Most participants who attended the initial in-office eye exam were single (76.4%), retired (63.2%), and had completed less than high school or high school education (64.6%). A significant proportion of participants who adhered (43.6%) spoke Spanish as their primary language (<italic toggle="yes">P</italic> &#x0003c; 0.001) (<xref rid="T2" ref-type="table">Table 2</xref>).</p></sec><sec id="S36"><title>Ocular and Medical History:</title><p id="P39">As shown in <xref rid="T2" ref-type="table">Table 2</xref>, of the 220 participants who adhered to the in-office eye exam, 67.7% self-reported hypertension and 31.4% self-reported diabetes. Additionally, of those who adhered, 21.4% of participants self-reported a family history of glaucoma and 19.1% self-reported glaucoma, both significantly different than those who did not adhere (<italic toggle="yes">P</italic> = 0.026). Regarding access to eye care, 40% of participants who completed the initial in-office eye exam had not had a dilated eye exam in the past 2 years, and 7.3%, or 16 participants had never had an eye exam.</p></sec><sec id="S37"><title>Eye Health Screenings:</title><p id="P40">Of 220 participants who adhered to the initial in-office eye exam, 82.3% failed the eye health screenings based on visual acuity 20/40 or worse, 11.4% failed due to IOP 23&#x02013;29 mmHg, and 21.4% failed due to having an unreadable image, with some having multiple reasons for failure (<xref rid="T3" ref-type="table">Table 3</xref>).</p></sec><sec id="S38"><title>Multivariate Stepwise Logistic Regression:</title><p id="P41">As shown in <xref rid="T4" ref-type="table">Table 4</xref>, participants in the Navigator Intervention group had higher odds of adhering to the initial in-office eye exam compared to those receiving Usual Care (OR = 1.529; 95% CI (1.023, 2.285); <italic toggle="yes">P</italic> = 0.038). Similarly, participants who spoke English as their primary language had higher odds of adhering to the initial eye exam (OR = 1.815; 95% Cl (1.211, 2721); <italic toggle="yes">P</italic> = 0.004). Participants with Medicaid insurance showed lower odds of adhering to the initial eye exam compared to those with Medicare or private insurance (OR = 0.636; 95% CI (0.430, 0.941); <italic toggle="yes">P</italic> = 0.023). Participants who self-reported glaucoma also had lower odds of adhering compared to those without pre-existing glaucoma (OR = 0.585; 95% CI (0.345, 0.994); <italic toggle="yes">P</italic> = 0.047) (<xref rid="T4" ref-type="table">Table 4</xref>). Although the initial chi-square test suggested that Hispanic participants and those who spoke Spanish as their primary language showed significantly higher adherence to in-office eye exams, the multivariate stepwise regression analysis revealed that Hispanic ethnicity and Spanish as a primary language were not significant predictors of adherence (<xref rid="T4" ref-type="table">Table 4</xref>).</p></sec><sec id="S39"><title>Ocular Diagnosis at Initial In-Office Eye Exam:</title><p id="P42">The initial in-office eye exams revealed a range of confirmed ocular diagnoses. Cataracts were the most common diagnosis, affecting 81 participants (36.8%), while the combined total of glaucoma and glaucoma suspect diagnoses accounted for 101 participants (45.9%). Other notable conditions included retinal abnormalities (14.1%), diabetic retinopathy (9.1%), and macular degeneration (7.3%).</p></sec><sec id="S40"><title>Treatment and Follow-Up Recommendations:</title><p id="P43">A variety of recommended treatment options ranged from close monitoring to ocular surgical and laser procedures. The majority of treatment recommendations were to 1) wait, watch, and follow IOP (57.7%); 2) prescribed IOP-lowering eye drops (20.9%), and 3) over-the-counter eye drops or ointment (16.4%). Additionally, 11.4% of participants were recommended for cataract surgery, while 7.3% were recommended for retinal or glaucoma surgery, including laser treatment. Follow-up recommended intervals were available in the EMR for 149 participants and ranged from within 4 weeks to 12 months for the next in-office dilated eye exam and ocular testing/imaging appointment.</p></sec><sec id="S41"><title>Cost Analysis Results:</title><p id="P44">The mean total staff time required to deliver the eye health screening and optometric exam was 40.12 minutes +16.04 per participant. The individual components of the cost analysis included:
<list list-type="bullet" id="L2"><list-item><p id="P45">Eye health screening (12.28 minutes +4.01).</p></list-item><list-item><p id="P46">Appointment management/scheduling (13.92 minutes +11.86).</p></list-item><list-item><p id="P47">Optometric exam time was 5.53 minutes +6.59 for the total number of participants.</p></list-item><list-item><p id="P48">For the 308 of 708 participants (43.5%) who received this optometric exam, mean optometric exam time was 11.44 minutes +4.71.</p></list-item><list-item><p id="P49">Total mean staff time cost, including all components, was $76.29 + $33.27 per participant.</p></list-item><list-item><p id="P50">Total cost of equipment, travel, and supplies was $103.96 per participant.</p></list-item><list-item><p id="P51">Total cost per participant was $180.88.</p></list-item><list-item><p id="P52">For those referred to ophthalmology for the in-office eye exam, the cost per case of eye disease detected was $273.64, based on the costs of delivering the program divided by the number of participants referred to ophthalmology (n = 468).<sup><xref rid="R17" ref-type="bibr">17</xref></sup></p></list-item></list></p><sec id="S42"><label>&#x02022;</label><title>COST OF THE NAVIGATOR INTERVENTION COMPARED TO USUAL CARE:</title><list list-type="bullet" id="L4"><list-item><p id="P53">Among the 468 participants referred to ophthalmology (trial sample), 3204 telephone calls were made, with a mean total duration of all calls of 9121 minutes, which cost $5879 or $13 per participant.</p></list-item><list-item><p id="P54">Participants in the Navigator Intervention group received a total of 2349 calls ($8.19 per participant) related to in-office eye exam appointments over 10 months.</p></list-item><list-item><p id="P55">Participants in Usual Care received 855 calls ($4.38 per participant) related to an abnormal image requiring referral and to schedule initial in-office eye exam appointments.</p></list-item><list-item><p id="P56">Of those participants referred to ophthalmology and reached by telephone, patient navigators spent additional time with scheduling and reminder telephone calls to confirm in-office eye exams, reschedule no-show or cancelled appointments, coordinating care with other eye doctors, and arrange transportation if requested.</p></list-item></list></sec><sec id="S43"><label>&#x02022;</label><title>COST EFFECTIVENESS:</title><list list-type="bullet" id="L6"><list-item><p id="P57">Cost per participant who attended the initial in-office eye exam for the Navigator Intervention group was $24.25 (total cost of phone calls [$3,830.91]/number of attended in-office appointments [n = 158]).</p></list-item><list-item><p id="P58">Cost per participant who attended the initial in-office eye exam for Usual Care was $33.03 ($2,047.58/62).</p></list-item><list-item><p id="P59">The Navigator Intervention compared to Usual Care was cost saving with an incremental cost-effectiveness difference of $8.78 less per participant randomized to the Navigator Intervention group.</p></list-item></list></sec></sec></sec><sec id="S44"><title>DISCUSSION</title><p id="P60">The Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) serves as a novel cluster-randomized clinical trial conducted in affordable housing developments and senior centers in Upper Manhattan. The NYC-SIGHT study incorporated patient navigators to support participants referred to ophthalmology to improve adherence to in-office eye exams by providing telephone-based appointment scheduling assistance and transportation if requested. This study offers a comprehensive understanding of the factors associated with adherence and compelling evidence supporting the beneficial role of patient navigators in helping underserved populations who may face disproportionate barriers to accessing adequate eye care.<sup><xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref></sup> Of the 220 screened participants who attended the initial in-office eye exam, a significantly greater proportion of participants (51.8%) were supported by patient navigators who assisted with telephone-based scheduling, appointment confirmation, and rescheduling.</p><p id="P61">The multivariate stepwise logistic regression model further reinforced the utility of the Navigator Intervention, as participants who received this support had significantly higher odds of adhering to the initial in-office eye exam compared to Usual Care participants. These findings are consistent with prior studies in various medical fields that have shown improvement in follow-up care adherence when patients are supported by navigators.<sup><xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R28" ref-type="bibr">28</xref>&#x02013;<xref rid="R34" ref-type="bibr">34</xref></sup> Additionally, participants who had English as their primary language also demonstrated significantly higher odds of adhering to the initial in-office eye exam. This aligns with existing literature, which identifies language barriers as a major obstacle to healthcare adherence, particularly in settings that rely on medical interpretation.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> Although several bilingual staff members were present at our community screenings, future studies should explore expanding the use of bilingual personnel, including patient navigators, to further reduce language-related barriers to care.</p><p id="P62">Conversely, participants with Medicaid or self-reported glaucoma had significantly lower odds of adhering to the initial in-office eye exam. These results corroborate prior research indicating that Medicaid recipients with glaucoma are significantly less likely to receive necessary testing and care compared to those with commercial insurance.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> The challenges faced by individuals with glaucoma in maintaining care are further compounded by SDOH, such as lower education and income levels, both of which were prevalent in the study population.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> These findings underscore the urgent need to implement patient navigators to help reduce barriers to eye care, and future studies should investigate utilizing navigators to assist with insurance navigation.</p><p id="P63">Of participants who attended the in-office eye exam, only 30% reported having their own eye doctor, 40% had not undergone a dilated eye exam in over 2 years, and 7.3% never had an eye exam. These results further illustrate the necessity of additional assistance, such as that provided by patient navigators, to effectively mitigate eye health disparities and improve access to and utilization of eye care in high-risk, underserved populations.<sup><xref rid="R32" ref-type="bibr">32</xref>&#x02013;<xref rid="R33" ref-type="bibr">33</xref></sup></p><sec id="S45"><label>&#x02022;</label><title>STRENGTHS:</title><p id="P64">This study considered social determinants by conducting eye health screenings in the community where participants live, thereby reducing access to care barriers. As hypothesized, more participants benefitted from the Navigator Intervention, justifying the 2:1 randomization study design. The study personnel scheduled in-office eye exams for all study participants referred to ophthalmology and provided patient navigation support at no cost to those in the Navigator Intervention group. This Navigator Intervention model could be crucial in improving eye care access and utilization in high-risk, underserved communities with the potential to be replicated and scaled in other settings.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup> The cost to yield adherence to the initial in-office eye exam revealed the Navigator Intervention cost less ($24.25 per participant) than Usual Care ($33.03 per participant).</p></sec><sec id="S46"><label>&#x02022;</label><title>LIMITATIONS:</title><p id="P65">Limitations of this study include the recruitment of adults and seniors from affordable housing in Upper Manhattan who self-selected to participate, which may not represent all high-risk populations in New York City or other urban settings. Although transportation was not a barrier in our urban setting, traveling to eye care providers may remain challenging in other geographic locations.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> Further, the lack of a consistent definition for adherence limits comparability with prior studies that have investigated follow-up adherence. In addition, the economic analysis only considered the cost of conducting the phone calls. Other potentially relevant costs include those related to infrastructure support. In addition, the economic analysis evaluated cost per adherent office visit and did not consider quality adjusted life years. Lastly, factors such as physical disabilities were not investigated, and these may influence adherence to attending in-office eye exams. Addressing these limitations in future research will be essential to better understand and enhance eye care access and utilization in diverse populations.</p><p id="P66">To conclude, the NYC-SIGHT Study is a novel community-based eye health screening study that incorporated optometric exams and patient navigators following screenings to improve in-office eye exam adherence in underserved participants who were referred to ophthalmology and tracked program costs. Among participants who adhered to the initial in-office eye exam, a significantly greater proportion received assistance from patient navigators (51.8%) compared to Usual care (38.1%), with the multivariate stepwise analysis confirming that participants in the Navigator Intervention group had higher odds of adherence. The cost per adherent in-office eye exam was lower in the Navigator Intervention compared to Usual Care. Based on these findings, we plan to continue partnering with NYCHA to scale eye health screenings in Upper Manhattan affordable housing developments to provide much needed evidence that may support policy changes to improve access to and utilization of eye care for underserved populations in the United States.</p></sec></sec></body><back><ack id="S48"><title>Acknowledgment:</title><p id="P68">The authors thank the CDC for funding the Manhattan Vision Screening and Follow-up Study (NYC-SIGHT) and our project officer, Jinan Saaddine, MD, MPH for her guidance and support for the SIGHTSTUDIES. We thank our Columbia University advisors from the Wellness Center (Olajide Williams, MD), Department of Government and Community Affairs (Ross A. Frommer, Esq.), School of Nursing (Steven Ferrara, DNP, FNP-BC), Mailman School of Public Health (Linda P. Fried, MD, MPH), Internal Medicine (Rafael A. Lantigua, MD), and Occupational Therapy (Phyllis Simon, OTD, OTR/L); New York City community partners: New York City Housing Authority (NYCHA) (Marina Oteiza); NYC Department for the Aging (Lorraine Cort&#x000e9;s-V&#x000e1;zquez and Edgar Yu) and DFTA Senior Center Directors; NYC Department of Health and Mental Hygiene; New York Academy of Medicine; Lighthouse Guild; Vision Services for the Blind and Visually Impaired; and Volk Optical, Inc. We thank Warby Parker for providing complementary eyeglasses. We thank our Data and Safety Monitoring Board: David S. Friedman, MD, PhD, MPH (Massachusetts Eye and Ear Infirmary), Cynthia Owsley, PhD, MPH (University of Alabama at Birmingham), Jonathan S. Myers, MD (Wills Eye Hospital), Benjamin E. Leiby, PhD (Jefferson Medical College), David Weiss, PhD (Ohio State University), and Tarun Sharma, MD (Columbia University Ophthalmology) for advising us on the study design, clinical decision making, and evaluation of outcomes. We also thank our community health educators (Jacqueline Wright and Rachel Wint) for participating in all screenings.</p><sec id="S49"><title>Funding/Support:</title><p id="P69">United States Centers for Disease Control and Prevention (CDC) Cooperative Agreements: U01DP006435, U01DP006436. Vision Health Initiative, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia. An unrestricted grant from Research to Prevent Blindness, Inc. (RPB) (New York, NY) provided ongoing support to Columbia University Department of Ophthalmology. The sponsor or funding organizations had no role in the design or conduct of this research.</p></sec><sec id="S50"><title>Financial Disclosures:</title><p id="P70">The authors indicate no financial support or conflicts of interest. All authors have completed and submitted the ICMJE disclosures form.</p></sec></ack><fn-group><fn id="FN1"><p id="P71">CREDIT AUTHORSHIP CONTRIBUTION STATEMENT</p><p id="P72"><bold>LISA A. HARK:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization. <bold>PRAKASH GORROOCHURN:</bold> Writing &#x02013; review &#x00026;. editing, Validation, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. <bold>LAURA T. PIZZI:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Resources, Methodology, Conceptualization. <bold>ERIC JUTKOWITZ:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Resources, Methodology, Conceptualization. <bold>ANNETTE M. GOULAK:</bold> Writing &#x02013; review <bold>&#x00026;</bold> editing. <bold>STEFANIA C. MARURI:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Software, Resources, Project administration, Methodology, Investigation. <bold>NOGA HARIZMAN:</bold> Writing &#x02013; review &#x00026; editing, Resources, Methodology, Investigation. <bold>JASON D. HOROWITZ:</bold> Writing &#x02013; review &#x00026; editing, Resources, Methodology, Investigation, Conceptualization. <bold>LISA PARK:</bold> Writing &#x02013; review &#x00026;. editing, Resources, Methodology, Investigation, Conceptualization. <bold>QING WANG:</bold> Writing &#x02013; review &#x00026; editing, Resources, Methodology, Investigation. <bold>DANIEL F. DIAMOND:</bold> Writing &#x02013; review &#x00026; editing, Resources, Methodology, Investigation. <bold>IVES A. VALENZUELA:</bold> Writing &#x02013; review &#x00026; editing, Resources, Methodology, Investigation. <bold>DESIREE R. TORRES:</bold> Writing &#x02013; review &#x00026;. editing, Writing &#x02013; original draft, Software, Resources, Project administration, Methodology, Investigation. <bold>YUJIA WANG:</bold> Writing &#x02013; review &#x00026; editing, Software, Resources, Project administration, Methodology, Investigation. <bold>TARUN SHARMA:</bold> Writing &#x02013; review &#x00026; editing, Resources, Methodology. <bold>JEFFREY M. LIEBMANN:</bold> Writing &#x02013; review &#x00026; editing, Resources, Methodology, Funding acquisition, Conceptualization. <bold>GEORGE A. CIOFFI:</bold> Writing &#x02013; review &#x00026; editing, Resources, Methodology, Funding acquisition, Conceptualization.</p></fn></fn-group><sec sec-type="data-availability" id="S47"><title>DATA SHARING STATEMENT</title><p id="P67">All deidentified participant data, study protocol, statistical plan, and informed consent will be made available by the corresponding author upon email request. The data will be made available with investigator support after approval of a proposal and a signed data access agreement is fully executed. NYC-SIGHT <italic toggle="yes">Clinical Protocol</italic> and <italic toggle="yes">Manual of Procedures</italic> are available at <ext-link xlink:href="http://SIGHTSTUDIES.org" ext-link-type="uri">SIGHTSTUDIES.org</ext-link>.</p></sec><glossary><title>Abbreviations:</title><def-list><def-item><term>CDC</term><def><p id="P73">Centers for Disease Control and Prevention</p></def></def-item><def-item><term>DFTA</term><def><p id="P74">Department for the Aging</p></def></def-item><def-item><term>EMR</term><def><p id="P75">Electronic medical record</p></def></def-item><def-item><term>HIPAA</term><def><p id="P76">Health Insurance Portability and Accountability Act</p></def></def-item><def-item><term>IOP</term><def><p id="P77">intraocular pressure</p></def></def-item><def-item><term>IRB</term><def><p id="P78">Institutional Review Board</p></def></def-item><def-item><term>logMAR</term><def><p id="P79">logarithm of the minimum angle of resolution</p></def></def-item><def-item><term>NEI</term><def><p id="P80">National Eye Institute</p></def></def-item><def-item><term>NYC</term><def><p id="P81">New York City</p></def></def-item><def-item><term>NYCHA</term><def><p id="P82">New York City Housing Authority</p></def></def-item><def-item><term>REDCap</term><def><p id="P83">Research Electronic Data Capture</p></def></def-item><def-item><term>SD</term><def><p id="P84">Standard Deviation</p></def></def-item><def-item><term>SDOH</term><def><p id="P85">social determinants of health</p></def></def-item><def-item><term>US</term><def><p id="P86">United States</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="book"><collab>Centers for Disease Control and Prevention</collab>. <source>Why Vision Loss Is a Public Health Problem</source>. <publisher-name>CDC</publisher-name>; <year>2024</year> Accessed <date-in-citation>October 1</date-in-citation>
<ext-link xlink:href="https://www.cdc.gov/vision-health/data-research/vision-loss-facts/index.html" ext-link-type="uri">https://www.cdc.gov/vision-health/data-research/vision-loss-facts/index.html</ext-link>.</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><article-title>Vision Loss Expert Group of the Global Burden of Disease StudyCauses of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study</article-title>. <source>Lancet Glob Health</source>. <year>2021</year>;<volume>9</volume>(<issue>2</issue>):<fpage>e144</fpage>&#x02013;<lpage>e160</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2214-109X(20)30489-7</pub-id>.<pub-id pub-id-type="pmid">33275949</pub-id>
</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Elam</surname><given-names>AR</given-names></name>, <name><surname>Tseng</surname><given-names>VL</given-names></name>, <name><surname>Rodriguez</surname><given-names>TM</given-names></name>, <etal/>
<article-title>Disparities in vision health and eye care</article-title>. <source>Ophthalmology</source>. <year>2022</year>;<volume>129</volume>(<issue>10</issue>):<fpage>e89</fpage>&#x02013;<lpage>e113</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ophtha.2022.07.010</pub-id>.<pub-id pub-id-type="pmid">36058735</pub-id>
</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><article-title>Social determinants of health and glaucoma screening and detection in the SIGHT Studies</article-title>. <source>J Glaucoma</source>. <year>2024</year> Published online. doi:<pub-id pub-id-type="doi">10.1097/IJG.0000000000002398</pub-id>.</mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Scott</surname><given-names>AW</given-names></name>, <name><surname>Elam</surname><given-names>AR</given-names></name>, <name><surname>Nwanyanwu</surname><given-names>K</given-names></name>. <article-title>Addressing disparities in eye care-the time is now</article-title>. <source>JAMA Ophthalmol</source>. <year>2021</year>;<volume>139</volume>(<issue>9</issue>):<fpage>935</fpage>&#x02013;<lpage>936</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaophthalmol.2021.2053</pub-id>.<pub-id pub-id-type="pmid">34351375</pub-id>
</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Alfaro Hudak</surname><given-names>KM</given-names></name>, <name><surname>Wittenborn</surname><given-names>JS</given-names></name>, <name><surname>Lamuda</surname><given-names>PA</given-names></name>, <name><surname>Lundeen</surname><given-names>EA</given-names></name>, <name><surname>Saaddine</surname><given-names>J</given-names></name>, <name><surname>Rein</surname><given-names>DB</given-names></name>. <article-title>Association between social determinants of health and examination-based vision loss vs self-reported vision measures</article-title>. <source>JAMA Ophthalmol</source>. <year>2023</year>;<volume>141</volume>(<issue>5</issue>):<fpage>468</fpage>&#x02013;<lpage>476</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaophthalmol.2023.0723</pub-id>.<pub-id pub-id-type="pmid">37022712</pub-id>
</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Solomon</surname><given-names>SD</given-names></name>, <name><surname>Shoge</surname><given-names>RY</given-names></name>, <name><surname>Ervin</surname><given-names>AM</given-names></name>, <etal/>
<article-title>Improving access to eye care: a systematic review of the literature</article-title>. <source>Ophthalmology</source>. <year>2022</year>;<volume>129</volume>(<issue>10</issue>):<fpage>e114</fpage>&#x02013;<lpage>e126</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ophtha.2022.07.012</pub-id>.<pub-id pub-id-type="pmid">36058739</pub-id>
</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="book"><name><surname>Chiang</surname><given-names>MF</given-names></name>. <source>NEI Strategic Plan Vision for the Future</source>. <publisher-name>NIH National Eye Institute</publisher-name>; <year>2024</year> Accessed <date-in-citation>October 1</date-in-citation>
<ext-link xlink:href="https://www.nei.nih.gov/sites/default/files/2021-10/NEI-StrategicPlan-ExecutiveSummary-508c.pdf" ext-link-type="uri">https://www.nei.nih.gov/sites/default/files/2021-10/NEI-StrategicPlan-ExecutiveSummary-508c.pdf</ext-link>.</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>van Zyl</surname><given-names>T</given-names></name>, <name><surname>Su</surname><given-names>Z</given-names></name>, <name><surname>Zhou</surname><given-names>E</given-names></name>, <etal/>
<article-title>Providing prescheduled appointments as a strategy for improving follow-up compliance after community-based glaucoma screening: results from an urban underserved population</article-title>. <source>J Community Health</source>. <year>2015</year>;<volume>40</volume>(<issue>1</issue>):<fpage>27</fpage>&#x02013;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10900-014-9890-2</pub-id>.<pub-id pub-id-type="pmid">24880821</pub-id>
</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>D</given-names></name>, <name><surname>Guallar</surname><given-names>E</given-names></name>, <name><surname>Bowie</surname><given-names>JV</given-names></name>, <etal/>
<article-title>Improving follow-up and reducing barriers for eye screenings in communities: The SToP Glaucoma Study</article-title>. <source>Am J Ophthalmol</source>. <year>2018</year>;<volume>188</volume>:<fpage>19</fpage>&#x02013;<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajo.2018.01.008</pub-id>.<pub-id pub-id-type="pmid">29355481</pub-id>
</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Hark</surname><given-names>LA</given-names></name>, <name><surname>Johnson</surname><given-names>DM</given-names></name>, <name><surname>Berardi</surname><given-names>G</given-names></name>, <etal/>
<article-title>A randomized, controlled trial to test the effectiveness of a glaucoma patient navigator to improve appointment adherence</article-title>. <source>Patient Prefer Adherence</source>. <year>2016</year>;<volume>10</volume>:<fpage>1739</fpage>&#x02013;<lpage>1748</lpage>. doi:<pub-id pub-id-type="doi">10.2147/PPA.S108391</pub-id>.<pub-id pub-id-type="pmid">27660423</pub-id>
</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Parker</surname><given-names>VA</given-names></name>, <name><surname>Clark</surname><given-names>JA</given-names></name>, <name><surname>Leyson</surname><given-names>J</given-names></name>, <etal/>
<article-title>Patient navigation: development of a protocol for describing what navigators do</article-title>. <source>Health Serv Res</source>. <year>2010</year>;<volume>45</volume>(<issue>2</issue>):<fpage>514</fpage>&#x02013;<lpage>531</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1475-6773.2009.01079.x</pub-id>.<pub-id pub-id-type="pmid">20132342</pub-id>
</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Rathinavelu</surname><given-names>JK</given-names></name>, <name><surname>Muir</surname><given-names>KW</given-names></name>, <name><surname>Majette</surname><given-names>NT</given-names></name>, <etal/>
<article-title>Qualitative analysis of barriers and facilitators to glaucoma medication adherence in a randomized controlled trial intervention</article-title>. <source>Ophthalmol Glaucoma</source>. <year>2023</year>;<volume>6</volume>(<issue>6</issue>):<fpage>626</fpage>&#x02013;<lpage>635</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ogla.2023.06.002</pub-id>.<pub-id pub-id-type="pmid">37343624</pub-id>
</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Leiby</surname><given-names>BE</given-names></name>, <name><surname>Hegarty</surname><given-names>SE</given-names></name>, <name><surname>Zhan</surname><given-names>T</given-names></name>, <etal/>
<article-title>A randomized trial to improve adherence to follow-up eye examinations among people with glaucoma</article-title>. <source>Prev Chronic Dis</source>. <year>2021</year>;<volume>18</volume>:<fpage>E52</fpage>. doi:<pub-id pub-id-type="doi">10.5888/pcd18.200567</pub-id>.<pub-id pub-id-type="pmid">34014814</pub-id>
</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>De Moraes</surname><given-names>CG</given-names></name>, <name><surname>Hark</surname><given-names>LA</given-names></name>, <name><surname>Saaddine</surname><given-names>J</given-names></name>. <article-title>Screening and Interventions for Glaucoma and Eye Health Through Telemedicine (SIGHT) Studies</article-title>. <source>J Glaucoma</source>. <year>2021</year>;<volume>30</volume>(<issue>5</issue>):<fpage>369</fpage>&#x02013;<lpage>370</lpage>. doi:<pub-id pub-id-type="doi">10.1097/IJG.0000000000001782</pub-id>.<pub-id pub-id-type="pmid">33428354</pub-id>
</mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Hark</surname><given-names>LA</given-names></name>, <name><surname>Kresch</surname><given-names>YS</given-names></name>, <name><surname>De Moraes</surname><given-names>CG</given-names></name>, <etal/>
<article-title>Manhattan Vision Screening and Follow-up Study in Vulnerable Populations (NYC-SIGHT): design and methodology</article-title>. <source>J Glaucoma</source>. <year>2021</year>;<volume>30</volume>(<issue>5</issue>):<fpage>388</fpage>&#x02013;<lpage>394</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ijg.0000000000001795</pub-id>.<pub-id pub-id-type="pmid">33492894</pub-id>
</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Hark</surname><given-names>LA</given-names></name>, <name><surname>Horowitz</surname><given-names>JD</given-names></name>, <name><surname>Gorroochum</surname><given-names>P</given-names></name>, <etal/>
<article-title>Manhattan Vision Screening and Follow-up Study (NYC-SIGHT): baseline results and costs of a cluster-randomized trial</article-title>. <source>Am J Ophthalmol</source>. <year>2023</year>;<volume>251</volume>:<fpage>12</fpage>&#x02013;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajo.2023.01.019</pub-id>.<pub-id pub-id-type="pmid">36690289</pub-id>
</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Hark</surname><given-names>LA</given-names></name>, <name><surname>Lin</surname><given-names>WV</given-names></name>, <name><surname>Hirji</surname><given-names>S</given-names></name>, <etal/>
<article-title>Manhattan Vision Screening and Follow-up Study (NYC-SIGHT): subanalysis of referral to ophthalmology</article-title>. <source>Curr Eye Res</source>. <year>2024</year>;<volume>49</volume>(<issue>2</issue>):<fpage>197</fpage>&#x02013;<lpage>206</lpage>. doi:<pub-id pub-id-type="doi">10.1080/02713683.2023.2269614</pub-id>.<pub-id pub-id-type="pmid">37812506</pub-id>
</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><article-title>The Mayor&#x02019;s Office for Economic Opportunity The New York City Government Poverty Measure</article-title>. <source>NYC Opportunity</source>. <year>2024</year>. Accessed <date-in-citation>October 1</date-in-citation>. <ext-link xlink:href="https://www.nyc.gov/site/opportunity/poverty-in-nyc/poverty-measure.page" ext-link-type="uri">https://www.nyc.gov/site/opportunity/poverty-in-nyc/poverty-measure.page</ext-link>.</mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <source>WHO. Blindness and Visual Impairment</source>; <year>2024</year> Accessed <date-in-citation>October 1</date-in-citation>
<ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment</ext-link>.</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Horowitz</surname><given-names>JD</given-names></name>, <name><surname>Adeghate</surname><given-names>JO</given-names></name>, <name><surname>Kania</surname><given-names>R</given-names></name>. <article-title>Manhattan Vision Screening and Follow-up Study (NYC-SIGHT): tele-retinal image findings and importance of photography</article-title>. <source>Telemed J E Health</source>. <year>2024</year>;<volume>30</volume>(<issue>3</issue>):<fpage>664</fpage>&#x02013;<lpage>676</lpage>. doi:<pub-id pub-id-type="doi">10.1089/tmj.2023.0134</pub-id>.<pub-id pub-id-type="pmid">37651209</pub-id>
</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Gedde</surname><given-names>SJ</given-names></name>, <name><surname>Lind</surname><given-names>JT</given-names></name>, <name><surname>Wright</surname><given-names>MM</given-names></name>, <etal/>
<article-title>Primary open-angle glaucoma suspect preferred practice pattern<sup>&#x000ae;</sup></article-title>. <source>Ophthalmobgy</source>. <year>2021</year>; <volume>128</volume>(<issue>1</issue>):<fpage>P151</fpage>&#x02013;<lpage>P192</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ophtha.2020.10.023</pub-id>.</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Diamond</surname><given-names>DF</given-names></name>, <name><surname>Hirji</surname><given-names>S</given-names></name>, <name><surname>Xing</surname><given-names>SX</given-names></name>, <etal/>
<article-title>Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT): optometric exam improves access and utilization of eye care services</article-title>. <source>Graefes Arch Clin Exp Ophthalmol</source>. <year>2024</year>;<volume>262</volume>(<issue>5</issue>):<fpage>1619</fpage>&#x02013;<lpage>1631</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00417-023-06344-2</pub-id>.<pub-id pub-id-type="pmid">38189973</pub-id>
</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Diamond</surname><given-names>DF</given-names></name>, <name><surname>Kresch</surname><given-names>YS</given-names></name>, <name><surname>Gorroochum</surname><given-names>P</given-names></name>, <article-title>Manhattan etal. Vision Screening and Follow-up Study (NYC-SIGHT): vision and refractive error results</article-title>. <source>Clin Exp Optom</source>. <year>2024</year>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08164622.2024.2322523</pub-id>.</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="other"><collab>IBM Corp</collab>. <source>IBM SPSS Statistics for Windows, Version 28.0</source>. <year>2021</year>.</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Kaplan</surname><given-names>RS</given-names></name>, <name><surname>Anderson</surname><given-names>SR</given-names></name>. <article-title>Time-driven activity-based costing</article-title>. <source>Harv Bus Rev</source>. <year>2004</year>;<volume>82</volume>(<issue>11</issue>):<fpage>131</fpage>&#x02013;<lpage>150</lpage>.</mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="book"><collab>U.S. Bureau of Labor Statistics</collab>. <source>Occupational Employment and Wage Statistics</source>. <publisher-name>U.S. Bureau of Labor Statistics</publisher-name>; <year>2024</year> Accessed <date-in-citation>October 1</date-in-citation>
<ext-link xlink:href="https://www.bls.gov/oes/current/oes291041.htm" ext-link-type="uri">https://www.bls.gov/oes/current/oes291041.htm</ext-link>.</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Starbird</surname><given-names>LE</given-names></name>, <name><surname>DiMaina</surname><given-names>C</given-names></name>, <name><surname>Sun</surname><given-names>CA</given-names></name>, <name><surname>Han</surname><given-names>HR</given-names></name>. <article-title>A systematic review of interventions to minimize transportation barriers among people with chronic diseases</article-title>. <source>J Community Health</source>. <year>2019</year>;<volume>44</volume>(<issue>2</issue>):<fpage>400</fpage>&#x02013;<lpage>411</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10900-018-0572-3</pub-id>.<pub-id pub-id-type="pmid">30206755</pub-id>
</mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Freund</surname><given-names>KM</given-names></name>, <name><surname>Battaglia</surname><given-names>TA</given-names></name>, <name><surname>Calhoun</surname><given-names>E</given-names></name>, <etal/>
<article-title>National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures</article-title>. <source>Cancer</source>. <year>2008</year>;<volume>113</volume>(<issue>12</issue>):<fpage>3391</fpage>&#x02013;<lpage>3399</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.23960</pub-id>.<pub-id pub-id-type="pmid">18951521</pub-id>
</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Fleisher</surname><given-names>L</given-names></name>, <name><surname>Miller</surname><given-names>SM</given-names></name>, <name><surname>Crookes</surname><given-names>D</given-names></name>, <etal/>
<article-title>Implementation of a theory-based, nonclinical patient navigator program to address barriers in an urban cancer center setting</article-title>. <source>J Oncol Navig Surviv</source>. <year>2012</year>;<volume>3</volume>(<issue>3</issue>):<fpage>14</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">25383260</pub-id>
</mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Wasser</surname><given-names>LM</given-names></name>, <name><surname>Bear</surname><given-names>TM</given-names></name>, <name><surname>Sommers</surname><given-names>M</given-names></name>, <name><surname>Cassidy</surname><given-names>J</given-names></name>, <name><surname>Muir</surname><given-names>KW</given-names></name>, <name><surname>Williams</surname><given-names>AM</given-names></name>. <article-title>Barriers to care among glaucoma patients with a missed appointment and interest in a navigator program</article-title>. <source>J Glaucoma</source>. <year>2024</year>;<volume>33</volume>(<issue>4</issue>):<fpage>297</fpage>&#x02013;<lpage>302</lpage>. doi:<pub-id pub-id-type="doi">10.1097/IJG.0000000000002330</pub-id>.<pub-id pub-id-type="pmid">37974342</pub-id>
</mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Hicks</surname><given-names>PM</given-names></name>, <name><surname>Asare</surname><given-names>AO</given-names></name>, <name><surname>Woodward</surname><given-names>MA</given-names></name>. <article-title>Beyond accessibility in exploring access to eye care to achieve vision health equity</article-title>. <source>JAMA Ophthalmol</source>. <year>2023</year>; <volume>141</volume> (<issue>8</issue>):<fpage>784</fpage>&#x02013;<lpage>785</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaophthalmol.2023.3196</pub-id>.<pub-id pub-id-type="pmid">37471057</pub-id>
</mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Atta</surname><given-names>S</given-names></name>, <name><surname>Zaheer</surname><given-names>HA</given-names></name>, <name><surname>Clinger</surname><given-names>O</given-names></name>, <etal/>
<article-title>Characteristics associated with barriers to eye care: a cross-sectional survey at a free vision screening event</article-title>. <source>Ophthalmic Res</source>. <year>2023</year>;<volume>66</volume>(<issue>1</issue>):<fpage>170</fpage>&#x02013;<lpage>178</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000526875</pub-id>.<pub-id pub-id-type="pmid">36063808</pub-id>
</mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Hark</surname><given-names>LA</given-names></name>, <name><surname>Johnson</surname><given-names>DM</given-names></name>, <name><surname>Berardi</surname><given-names>G</given-names></name>, <etal/>
<article-title>A randomized, controlled trial to test the effectiveness of a glaucoma patient navigator to improve appointment adherence</article-title>. <source>Patient Prefer Adherence</source>. <year>2016</year>;<volume>10</volume>:<fpage>1739</fpage>&#x02013;<lpage>1748</lpage>. doi:<pub-id pub-id-type="doi">10.2147/PPA.S108391</pub-id>.<pub-id pub-id-type="pmid">27660423</pub-id>
</mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>BW</given-names></name>, <name><surname>Murakami</surname><given-names>Y</given-names></name>, <name><surname>Duncan</surname><given-names>MT</given-names></name>, <etal/>
<article-title>Patient-related and system-related barriers to glaucoma follow-up in a county hospital population</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2013</year>;<volume>54</volume>(<issue>10</issue>):<fpage>6542</fpage>&#x02013;<lpage>6548</lpage>. doi:<pub-id pub-id-type="doi">10.1167/iovs.13-12108</pub-id>.<pub-id pub-id-type="pmid">23982843</pub-id>
</mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Elam</surname><given-names>AR</given-names></name>, <name><surname>Andrews</surname><given-names>C</given-names></name>, <name><surname>Musch</surname><given-names>DC</given-names></name>, <name><surname>Lee</surname><given-names>PP</given-names></name>, <name><surname>Stein</surname><given-names>JD</given-names></name>. <article-title>Large disparities in receipt of glaucoma care between enrollees in Medicaid and those with commercial health insurance</article-title>. <source>Ophthalmology</source>. <year>2017</year>;<volume>124</volume>(<issue>10</issue>):<fpage>1442</fpage>&#x02013;<lpage>1448</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ophtha.2017.05.003</pub-id>.<pub-id pub-id-type="pmid">28583710</pub-id>
</mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>JH</given-names></name>, <name><surname>Varkhedi</surname><given-names>V</given-names></name>, <name><surname>Radha Saseendrakumar</surname><given-names>B</given-names></name>, <name><surname>Acuff</surname><given-names>K</given-names></name>, <name><surname>Weinreb</surname><given-names>RN</given-names></name>, <name><surname>Baxter</surname><given-names>SL</given-names></name>. <article-title>Social and health care utilization factors associated with ophthalmic visit nonadherence in glaucoma: an All of Us Study</article-title>. <source>J Glaucoma</source>. <year>2023</year>;<volume>32</volume>(<issue>12</issue>):<fpage>1029</fpage>&#x02013;<lpage>1037</lpage>. doi:<pub-id pub-id-type="doi">10.1097/IJG.0000000000002300</pub-id>.<pub-id pub-id-type="pmid">37671531</pub-id>
</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>FIGURE 1.</label><caption><p id="P87">CONSORT Diagram shows study flowchart. Participants were recruited via flyer distribution (Top center). Verbal informed consent, intake data, medical, ocular, and falls history, NEI VFQ-9 survey and COVID-19 history were obtained via the call center prior to eye health screening (second row). All enrolled participants were scheduled for eye health screenings at the NYCHA Developments and DFTA senior centers (third row). Reasons for not attending eye health screening (third row right). Eye health screening outcomes were normal, failed screening, or abnormal/fast-track (fourth row). All participants who failed the eye health screening were scheduled with the on-site optometrist (fifth row). Optometrist diagnoses included refractive error (sixth row). Usual Care group received eyeglasses prescription only. Navigator Intervention group received complimentary eyeglasses (seventh row left). Total participants referred to ophthalmology (eighth row right). Intervention participants referred to ophthalmology were assisted by patient navigators while Usual Care group were not supported (ninth row). Total attendance at the initial in-office eye exam between Usual Care and Navigator Intervention groups (Last row). Reasons for not attending the in-office eye exam are shown (ninth row left).</p></caption><graphic xlink:href="nihms-2126947-f0001" position="float"/></fig><table-wrap position="float" id="T1" orientation="landscape"><label>TABLE 1.</label><caption><p id="P88">NYC-SIGHT: Adherence Rates, Demographics, and Social Determinants of Health for Participants Referred for Initial In-Office Eye Exam by Randomization Group (n = 468)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variable</th><th align="center" valign="top" rowspan="1" colspan="1">Navigator Intervention group (n = 305)</th><th align="center" valign="top" rowspan="1" colspan="1">Usual Care group (n = 163)</th><th align="center" valign="top" rowspan="1" colspan="1">P Value<sup><xref rid="TFN2" ref-type="table-fn">a</xref></sup></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, mean (&#x000b1;SD)</td><td align="center" valign="top" rowspan="1" colspan="1">69.43 (11.57)</td><td align="center" valign="top" rowspan="1" colspan="1">71.13 (11.15)</td><td align="center" valign="top" rowspan="1" colspan="1">.122<sup><xref rid="TFN5" ref-type="table-fn">d</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age category, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;40&#x02013;59 years</td><td align="center" valign="top" rowspan="1" colspan="1">66 (21.6)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (14.1)</td><td align="center" valign="top" rowspan="1" colspan="1">.142</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;60&#x02013;79 years</td><td align="center" valign="top" rowspan="1" colspan="1">181 (59.3)</td><td align="center" valign="top" rowspan="1" colspan="1">106 (65.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02265;80 years</td><td align="center" valign="top" rowspan="1" colspan="1">58 (19.1)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (20.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.337</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" valign="top" rowspan="1" colspan="1">97 (31.8)</td><td align="center" valign="top" rowspan="1" colspan="1">59 (36.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" valign="top" rowspan="1" colspan="1">208 (68.2)</td><td align="center" valign="top" rowspan="1" colspan="1">104 (63.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race/ethnicity, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;African American</td><td align="center" valign="top" rowspan="1" colspan="1">149 (48.9)</td><td align="center" valign="top" rowspan="1" colspan="1">109 (66.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hispanic<sup><xref rid="TFN3" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">135 (44.3)</td><td align="center" valign="top" rowspan="1" colspan="1">50 (30.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" valign="top" rowspan="1" colspan="1">21 (6.9)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education level, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<bold>.005</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Less than high school</td><td align="center" valign="top" rowspan="1" colspan="1">96 (31.5)</td><td align="center" valign="top" rowspan="1" colspan="1">42 (25.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;High school</td><td align="center" valign="top" rowspan="1" colspan="1">113 (37.0)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (27.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Some college, college graduate, or graduate degree</td><td align="center" valign="top" rowspan="1" colspan="1">96 (31.5)</td><td align="center" valign="top" rowspan="1" colspan="1">76 (46.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Employment status, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.078</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Employed (full-time/part-time)</td><td align="center" valign="top" rowspan="1" colspan="1">49 (16.1)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (19.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unemployed</td><td align="center" valign="top" rowspan="1" colspan="1">35 (11.5)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (6.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Retired</td><td align="center" valign="top" rowspan="1" colspan="1">182 (59.7)</td><td align="center" valign="top" rowspan="1" colspan="1">108 (66.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Disabled/unable to work</td><td align="center" valign="top" rowspan="1" colspan="1">12 (7.4)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (7.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marital status, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<bold>.048</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Single, divorced, separated, or widowed</td><td align="center" valign="top" rowspan="1" colspan="1">224 (73.4)</td><td align="center" valign="top" rowspan="1" colspan="1">133 (81.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Married/Domestic partner</td><td align="center" valign="top" rowspan="1" colspan="1">81 (26.6)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (18.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Has health insurance, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.000<sup><xref rid="TFN5" ref-type="table-fn">d</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">9 (3.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">296 (97.0)</td><td align="center" valign="top" rowspan="1" colspan="1">158 (96.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insurance Type,<sup><xref rid="TFN4" ref-type="table-fn">c</xref></sup> n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Medicare</td><td align="center" valign="top" rowspan="1" colspan="1">183 (60.0)</td><td align="center" valign="top" rowspan="1" colspan="1">104 (63.8)</td><td align="center" valign="top" rowspan="1" colspan="1">.481</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Medicaid</td><td align="center" valign="top" rowspan="1" colspan="1">178 (48.4)</td><td align="center" valign="top" rowspan="1" colspan="1">81 (49.7)</td><td align="center" valign="top" rowspan="1" colspan="1">.072</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Private or supplemental</td><td align="center" valign="top" rowspan="1" colspan="1">87 (28.5)</td><td align="center" valign="top" rowspan="1" colspan="1">47 (28.8)</td><td align="center" valign="top" rowspan="1" colspan="1">.944</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary language, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;English</td><td align="center" valign="top" rowspan="1" colspan="1">171 (56.1)</td><td align="center" valign="top" rowspan="1" colspan="1">122 (74.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Spanish</td><td align="center" valign="top" rowspan="1" colspan="1">124 (40.7)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (25.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other (French/Creole/Arabic/Russian)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (3.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Has own eye doctor (access to eye care), n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.526</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">209 (68.5)</td><td align="center" valign="top" rowspan="1" colspan="1">107 (65.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">96 (31.5)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (34.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wears prescription eyeglasses, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.681</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">77 (25.2)</td><td align="center" valign="top" rowspan="1" colspan="1">44 (27.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">228 (74.8)</td><td align="center" valign="top" rowspan="1" colspan="1">119 (73.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Attended initial in-office eye exam</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<bold>.004</bold>
<sup>
<xref rid="TFN6" ref-type="table-fn">e</xref>
</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">158 (51.8)</td><td align="center" valign="top" rowspan="1" colspan="1">62 (38.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">147 (48.2)</td><td align="center" valign="top" rowspan="1" colspan="1">101 (61.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P89">SD = standard deviation.</p></fn><fn id="TFN2"><label>a</label><p id="P90">Bold <italic toggle="yes">P</italic> value indicates statistical significance at the <italic toggle="yes">P</italic> &#x02264; .05 level.</p></fn><fn id="TFN3"><label>b</label><p id="P91">Hispanic (n = 297) + Multiethnic (n = 17).</p></fn><fn id="TFN4"><label>c</label><p id="P92">For types of insurance variables, the levels were not mutually exclusive, so that the sum of the values may exceed 220 participants.</p></fn><fn id="TFN5"><label>d</label><p id="P93">Fisher&#x02019;s exact test, all other tests use Pearson chi-squared test.</p></fn><fn id="TFN6"><label>e</label><p id="P94">t-test.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="landscape"><label>TABLE 2.</label><caption><p id="P95">NYC-SIGHT: Demographics and Social Determinants of Health for Participants Referred for Initial In-Office Eye Exam by Adherence</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variable</th><th align="center" valign="top" rowspan="1" colspan="1">Attended initial in-office eye exam (n = 220)<sup><xref rid="TFN10" ref-type="table-fn">c</xref></sup></th><th align="center" valign="top" rowspan="1" colspan="1">Did not attend initial in-office eye exam (n = 248)<sup><xref rid="TFN10" ref-type="table-fn">c</xref></sup></th><th align="center" valign="top" rowspan="1" colspan="1">P Value<sup><xref rid="TFN8" ref-type="table-fn">a</xref></sup></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Randomization group Navigator Intervention group, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1">158 (51.8)</td><td align="center" valign="top" rowspan="1" colspan="1">147 (48.2)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>.004</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Usual Care group, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1">62 (38.1)</td><td align="center" valign="top" rowspan="1" colspan="1">101 (61.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, mean (&#x000b1;SD)</td><td align="center" valign="top" rowspan="1" colspan="1">70.2 (11.3)</td><td align="center" valign="top" rowspan="1" colspan="1">69.9 (11.6)</td><td align="center" valign="top" rowspan="1" colspan="1">.812</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age category, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.792</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;40&#x02013;59 years</td><td align="center" valign="top" rowspan="1" colspan="1">40 (18.2)</td><td align="center" valign="top" rowspan="1" colspan="1">49 (19.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;60&#x02013;79 years</td><td align="center" valign="top" rowspan="1" colspan="1">134 (60.9)</td><td align="center" valign="top" rowspan="1" colspan="1">153 (61.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02265;80 years</td><td align="center" valign="top" rowspan="1" colspan="1">46 (20.9)</td><td align="center" valign="top" rowspan="1" colspan="1">46 (18.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.624</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" valign="top" rowspan="1" colspan="1">76 (34.5)</td><td align="center" valign="top" rowspan="1" colspan="1">80 (32.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" valign="top" rowspan="1" colspan="1">144 (65.5)</td><td align="center" valign="top" rowspan="1" colspan="1">168 (67.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race/ethnicity, n, (%)<sup><xref rid="TFN9" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<bold>.003</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;African American</td><td align="center" valign="top" rowspan="1" colspan="1">103 (46.8)</td><td align="center" valign="top" rowspan="1" colspan="1">155 (62.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">104 (47.3)</td><td align="center" valign="top" rowspan="1" colspan="1">81 (32.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" valign="top" rowspan="1" colspan="1">13 (5.9)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (4.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education level, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.865</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Less than high school</td><td align="center" valign="top" rowspan="1" colspan="1">67 (30.5)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;High school</td><td align="center" valign="top" rowspan="1" colspan="1">75 (34.1)</td><td align="center" valign="top" rowspan="1" colspan="1">83 (33.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Some college, college graduate, or graduate degree</td><td align="center" valign="top" rowspan="1" colspan="1">78 (35.5)</td><td align="center" valign="top" rowspan="1" colspan="1">94 (37.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Employment Status, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.803</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Employed (full-time/part-time)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (15.5)</td><td align="center" valign="top" rowspan="1" colspan="1">47 (19.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unemployed</td><td align="center" valign="top" rowspan="1" colspan="1">22 (10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (9.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Retired</td><td align="center" valign="top" rowspan="1" colspan="1">139 (63.2)</td><td align="center" valign="top" rowspan="1" colspan="1">151 (60.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Disabled/unable to work</td><td align="center" valign="top" rowspan="1" colspan="1">25 (11.4)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (10.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marital status, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Single, divorced, separated, or widowed</td><td align="center" valign="top" rowspan="1" colspan="1">168 (76.4)</td><td align="center" valign="top" rowspan="1" colspan="1">189 (76.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Married/domestic partner</td><td align="center" valign="top" rowspan="1" colspan="1">52 (23.6)</td><td align="center" valign="top" rowspan="1" colspan="1">59 (23.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Has health insurance, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.052</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (4.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">217 (98.6)</td><td align="center" valign="top" rowspan="1" colspan="1">237 (95.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insurance Type<sup><xref rid="TFN10" ref-type="table-fn">c</xref></sup>, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Medicare</td><td align="center" valign="top" rowspan="1" colspan="1">133 (60.5)</td><td align="center" valign="top" rowspan="1" colspan="1">154 (62.1)</td><td align="center" valign="top" rowspan="1" colspan="1">.716</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Medicaid</td><td align="center" valign="top" rowspan="1" colspan="1">140 (63.6)</td><td align="center" valign="top" rowspan="1" colspan="1">119 (48.0)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Private or supplemental</td><td align="center" valign="top" rowspan="1" colspan="1">61 (27.7)</td><td align="center" valign="top" rowspan="1" colspan="1">73 (29.4)</td><td align="center" valign="top" rowspan="1" colspan="1">.683</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary language, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;.001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;English</td><td align="center" valign="top" rowspan="1" colspan="1">116 (52.7)</td><td align="center" valign="top" rowspan="1" colspan="1">177 (71.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Spanish</td><td align="center" valign="top" rowspan="1" colspan="1">96 (43.6)</td><td align="center" valign="top" rowspan="1" colspan="1">69 (27.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other (French/Creole/Arabic/Russian)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (3.6)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Has own eye doctor (access to eye care), n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">86 (34.7)</td><td align="center" valign="top" rowspan="1" colspan="1">.281</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wears prescription eyeglasses, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1">163 (74.1)</td><td align="center" valign="top" rowspan="1" colspan="1">184 (74.2)</td><td align="center" valign="top" rowspan="1" colspan="1">.980</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><p id="P96">SD = standard deviation.</p></fn><fn id="TFN8"><label>a</label><p id="P97">Bold <italic toggle="yes">P</italic> value indicates statistical significance at the <italic toggle="yes">P</italic> &#x02264; .05 level.</p></fn><fn id="TFN9"><label>b</label><p id="P98">Hispanic (n = 297) + Multiethnic (n = 17).</p></fn><fn id="TFN10"><label>c</label><p id="P99">For types of insurance variables, the levels were not mutually exclusive, so that the sum of the values may exceed 220 participants.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3" orientation="landscape"><label>TABLE 3.</label><caption><p id="P100">NYC-SIGHT: Medical and Ocular History, and Eye Health Screenings for Participants Referred for Initial In-Office Eye Exam by Adherence</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variable</th><th align="center" valign="top" rowspan="1" colspan="1">Attended initial in-office eye exam (n = 220)</th><th align="center" valign="top" rowspan="1" colspan="1">Did not attend initial in-office eye exam (n = 248)</th><th align="center" valign="top" rowspan="1" colspan="1">P Value<sup><xref rid="TFN12" ref-type="table-fn">a</xref></sup></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Last dilated eye exam, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.435</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Within the past year</td><td align="center" valign="top" rowspan="1" colspan="1">59 (26.8)</td><td align="center" valign="top" rowspan="1" colspan="1">67 (27.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Within 1 to 2 years</td><td align="center" valign="top" rowspan="1" colspan="1">56 (25.5)</td><td align="center" valign="top" rowspan="1" colspan="1">69 (27.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;More than 2 years</td><td align="center" valign="top" rowspan="1" colspan="1">88 (40.0)</td><td align="center" valign="top" rowspan="1" colspan="1">90 (36.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Can&#x02019;t remember</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Never had eye exam</td><td align="center" valign="top" rowspan="1" colspan="1">16 (7.3)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (6.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medical conditions, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">149 (67.7)</td><td align="center" valign="top" rowspan="1" colspan="1">158 (63.7)</td><td align="center" valign="top" rowspan="1" colspan="1">.361</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Diabetes</td><td align="center" valign="top" rowspan="1" colspan="1">69 (31.4)</td><td align="center" valign="top" rowspan="1" colspan="1">82 (33.1)</td><td align="center" valign="top" rowspan="1" colspan="1">.694</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ocular conditions, n, (%)<sup><xref rid="TFN13" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Dry eye</td><td align="center" valign="top" rowspan="1" colspan="1">106 (48.2)</td><td align="center" valign="top" rowspan="1" colspan="1">112 (45.2)</td><td align="center" valign="top" rowspan="1" colspan="1">.513</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Blurry vision</td><td align="center" valign="top" rowspan="1" colspan="1">85 (38.6)</td><td align="center" valign="top" rowspan="1" colspan="1">90 (36.3)</td><td align="center" valign="top" rowspan="1" colspan="1">.601</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Cataract</td><td align="center" valign="top" rowspan="1" colspan="1">69 (31.4)</td><td align="center" valign="top" rowspan="1" colspan="1">79 (31.9)</td><td align="center" valign="top" rowspan="1" colspan="1">.909</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Glaucoma</td><td align="center" valign="top" rowspan="1" colspan="1">42 (19.1)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (11.7)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>.026</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Floaters</td><td align="center" valign="top" rowspan="1" colspan="1">28 (12.7)</td><td align="center" valign="top" rowspan="1" colspan="1">44 (17.7)</td><td align="center" valign="top" rowspan="1" colspan="1">.133</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Double vision</td><td align="center" valign="top" rowspan="1" colspan="1">13 (5.9)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (5.6)</td><td align="center" valign="top" rowspan="1" colspan="1">.903</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Diabetic retinopathy</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">.740<sup><xref rid="TFN15" ref-type="table-fn">d</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Macular degeneration</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (.8)</td><td align="center" valign="top" rowspan="1" colspan="1">.262<sup><xref rid="TFN15" ref-type="table-fn">d</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No ocular conditions</td><td align="center" valign="top" rowspan="1" colspan="1">36 (16.4)</td><td align="center" valign="top" rowspan="1" colspan="1">58 (23.4)</td><td align="center" valign="top" rowspan="1" colspan="1">.058</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Family History, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Family history of glaucoma</td><td align="center" valign="top" rowspan="1" colspan="1">47 (21.4)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (26.6)</td><td align="center" valign="top" rowspan="1" colspan="1">.185</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Family history of blindness</td><td align="center" valign="top" rowspan="1" colspan="1">18 (8.2)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (11.7)</td><td align="center" valign="top" rowspan="1" colspan="1">.207</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Visual acuity based on worse eye, n, (%)<sup><xref rid="TFN13" ref-type="table-fn">b</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">.095</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No vision impairment: logMAR<sup><xref rid="TFN14" ref-type="table-fn">c</xref></sup> 0&#x02013;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">39 (17.7)</td><td align="center" valign="top" rowspan="1" colspan="1">55 (22.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mild vision impairment: logMAR<sup><xref rid="TFN14" ref-type="table-fn">c</xref></sup> 0.3&#x02013;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">68 (30.9)</td><td align="center" valign="top" rowspan="1" colspan="1">74 (29.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Moderate vision impairment: logMAR<sup><xref rid="TFN14" ref-type="table-fn">c</xref></sup> 0.5&#x02013;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">64 (29.1)</td><td align="center" valign="top" rowspan="1" colspan="1">84 (33.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Severe vision impairment: logMAR<sup><xref rid="TFN14" ref-type="table-fn">c</xref></sup> 1.0&#x02013;3.0</td><td align="center" valign="top" rowspan="1" colspan="1">49 (22.3)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (14.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IOP (mmHg), mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Left eye (n = 706)</td><td align="center" valign="top" rowspan="1" colspan="1">15.31 (5.10)</td><td align="center" valign="top" rowspan="1" colspan="1">14.69 (4.31)</td><td align="center" valign="top" rowspan="1" colspan="1">.157</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Right eye (n = 705)</td><td align="center" valign="top" rowspan="1" colspan="1">15.59 (5.33)</td><td align="center" valign="top" rowspan="1" colspan="1">14.60 (4.30)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>.029</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Failed screening, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1">190 (86.4)</td><td align="center" valign="top" rowspan="1" colspan="1">216 (87.1)</td><td align="center" valign="top" rowspan="1" colspan="1">.815</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reason for screening failure, n, (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Visual acuity 20/40 or worse in either eye</td><td align="center" valign="top" rowspan="1" colspan="1">181 (82.3)</td><td align="center" valign="top" rowspan="1" colspan="1">193 (77.8)</td><td align="center" valign="top" rowspan="1" colspan="1">.230</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;IOP 23&#x02013;29 mmHg</td><td align="center" valign="top" rowspan="1" colspan="1">25 (11.4)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (7.7)</td><td align="center" valign="top" rowspan="1" colspan="1">.171</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unreadable image</td><td align="center" valign="top" rowspan="1" colspan="1">47 (21.4)</td><td align="center" valign="top" rowspan="1" colspan="1">70 (28.2)</td><td align="center" valign="top" rowspan="1" colspan="1">.087</td></tr></tbody></table><table-wrap-foot><fn id="TFN11"><p id="P101">IOP = intraocular pressure; logMAR = logarithm of the minimum angle of resolution; SD = standard deviation.</p></fn><fn id="TFN12"><label>a</label><p id="P102">Bold <italic toggle="yes">P</italic> Value indicates statistical significance at the <italic toggle="yes">P</italic> &#x02264; .05 level.</p></fn><fn id="TFN13"><label>b</label><p id="P103">For self-reported ocular conditions, the levels were not mutually exclusive, so that the sum of the values may exceed 220 or 24.</p></fn><fn id="TFN14"><label>c</label><p id="P104">logMAR converted from Snellen eye chart visual acuity participants.</p></fn><fn id="TFN15"><label>d</label><p id="P105">Refers to Fisher&#x02019;s Exact Test, all other tests use the Pearson Chi-square.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4" orientation="landscape"><label>TABLE 4.</label><caption><p id="P106">NYC-SIGHT: Multivariate Stepwise<sup><xref rid="TFN18" ref-type="table-fn">b</xref></sup> Logistic Regression Model Estimating Factors Associated with Adherence to Initial In-Office Eye Exam for Participants Referred to Ophthalmology.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Variables</th><th align="center" valign="top" rowspan="1" colspan="1">OR</th><th align="center" valign="top" rowspan="1" colspan="1">95% CI</th><th align="center" valign="top" rowspan="1" colspan="1">P Value<sup><xref rid="TFN17" ref-type="table-fn">a</xref></sup></th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Randomization group</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Usual Care group</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Navigator Intervention group</td><td align="center" valign="top" rowspan="1" colspan="1">1.529</td><td align="center" valign="top" rowspan="1" colspan="1">(1.023, 2.285)</td><td align="center" valign="top" rowspan="1" colspan="1">0.038</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Language</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Non-English</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;English</td><td align="center" valign="top" rowspan="1" colspan="1">1.815</td><td align="center" valign="top" rowspan="1" colspan="1">(1.211, 2.721)</td><td align="center" valign="top" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Health insurance type</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;No Medicaid</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x02003;Medicaid</td><td align="center" valign="top" rowspan="1" colspan="1">0.636</td><td align="center" valign="top" rowspan="1" colspan="1">(0.430, 0.941)</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Self-reported glaucoma or glaucoma suspect</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">0.585</td><td align="center" valign="top" rowspan="1" colspan="1">(0.345, 0.994)</td><td align="center" valign="top" rowspan="1" colspan="1">0.047</td></tr></tbody></table><table-wrap-foot><fn id="TFN16"><p id="P107">IOP = intraocular pressure.</p></fn><fn id="TFN17"><label>a</label><p id="P108">Bold P Value indicates statistical significance at the <italic toggle="yes">P</italic> &#x02264; .05 level.</p></fn><fn id="TFN18"><label>b</label><p id="P109">At each step, variables were added based on the alpha-to-enter significance level of 0.05 and the alpha-to-remove significance level was set at 0.1 to exclude variables in the final model.</p></fn></table-wrap-foot></table-wrap></floats-group></article>